Eurasian Journal of Analytical Chemistry
ISSN: 1306-3057 OPEN ACCESS 2024 19 (1): 143-157

1,2,4,5-Tetraoxanes As New Chemical Entities With High Efficacy Against Malaria: Recent Advances In Drug Development

Yash Srivastav[1], Alka Verma[2], Neha Sharma[3], Juhi Saxena[4], Rajesh M Meshram[5], Aashutosh Shinha[6], Suman Kumar Rathore[7], Sanmati Kumar Jain[8], Anil Kumar[9*]

[1]Assistant Professor, Department of Pharmacy, Azad Institute of Pharmacy and Research, Lucknow, Uttar Pradesh, India
[2]Assistant Professor, Department of Pharmaceutical Chemistry, RGS college of Pharmacy. Near toll plaza Lucknow,Uttar Pradesh, India
[3]Assistant Professor, Department of Pharmaceutical Education and Research, Bhagat Phool Singh Mahila Vishwavidyala, Khanpur Kalan, Haryana, India
[4]Assistant Professor, Department of Pharmacy, Jhankar College of Pharmacy,Babra Bakipur, Gurugram, Haryana, India
[5]Assistant Professor, Department of Pharmaceutical Chemistry, School of Pharmacy, Chouksey Engineering College, Bilaspur, Chhattisgarh, India
[6]Scholar, Department of Pharmacy, School of Pharmacy, Chouksey Engineering College, Bilaspur, Chhattisgarh, India
[7]Assistant Professor, Department of Pharmacy, Tagore Institute of Pharmacy and Research Sakri Bilaspur, CSVTU, Bhilai, Chhattisgarh, India
[8]Professor, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Koni, Bilaspur, India
[9*]Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India

***Corresponding Author:** Anil Kumar
*Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India

Abstract
Malaria continues to pose a significant global health threat, with approximately 239 million cases and around 409,000 deaths reported in 2023, predominantly among young children in sub-Saharan Africa. The emergence of drug-resistant strains of Plasmodium necessitates the urgent development of new therapeutic agents. This review focuses on the recent advancements in the synthesis, mechanisms of action, and evaluations of 1,2,4,5-tetraoxanes, a promising new class of antimalarial agents. 1,2,4,5-tetraoxanes exhibit unique mechanisms of action, including the generation of reactive oxygen species (ROS) and the inhibition of heme detoxification, which are crucial for the survival of Plasmodium parasites. Their ability to induce oxidative stress and disrupt vital metabolic processes positions them as strong candidates for combating malaria, particularly in light of the limitations of existing treatments such as artemisinin-based combination therapies (ACTs). The review also highlights the historical context of tetraoxane development, detailing various synthetic methodologies, including traditional approaches and modern techniques such as microwave-assisted synthesis and metal-catalyzed reactions. These advancements not only improve yield and efficiency but also facilitate the exploration of diverse tetraoxane derivatives. As malaria remains a pressing health issue, continued research into 1,2,4,5-tetraoxanes is essential for overcoming challenges related to drug resistance and enhancing treatment outcomes for affected populations.

Keywords: Malaria, 1,2,4,5-tetraoxanes, Drug resistance, Antimalarial agents, Reactive oxygen species (ROS)

1. Introduction

Malaria remains a significant global health challenge, with approximately 229 million cases reported worldwide in 2019, resulting in around 409,000 deaths, primarily among young children in sub-Saharan Africa[1]. The disease is caused by the Plasmodium parasite, transmitted through the bite of infected Anopheles mosquitoes, and poses a major burden on healthcare systems, economies, and communities[2]. The limitations of current antimalarial therapies, particularly the emergence of drug-resistant strains of Plasmodium, necessitate the urgent development of novel therapeutic agents[3]. The first-line treatment options, including artemisinin-based combination therapies (ACTs), have been effective; however, resistance to artemisinin has been reported in several regions, reducing the efficacy of these treatments and leading to increased morbidity and mortality[4]. This highlights the need for new classes of antimalarial compounds that can effectively combat resistant strains and provide alternative therapeutic options. One promising class of compounds is the 1,2,4,5-tetraoxanes, a relatively new category of antimalarial agents that have garnered significant attention in recent years. Structurally, 1,2,4,5-tetraoxanes are characterized

by a unique tetraoxane ring system, which differentiates them from traditional antimalarial drugs[5]. The presence of multiple oxygen atoms in their structure is believed to contribute to their high reactivity and potential efficacy against malaria. Initial studies suggest that 1,2,4,5-tetraoxanes possess a distinct mechanism of action, which includes the generation of reactive oxygen species (ROS) and the inhibition of heme detoxification in Plasmodium parasites[6]. These properties position them as strong candidates for further exploration and development in the context of malaria treatment. Historically, the development of tetraoxanes began in the late 20th century, with the aim of discovering new chemical entities that could target malaria parasites effectively[7]. Since then, significant progress has been made in synthesizing various tetraoxane derivatives and evaluating their antimalarial activity through structure-activity relationship (SAR) studies. This historical context serves as a foundation for understanding the evolution of these compounds and their potential role in combating malaria[8]. The objective of this review is to summarize the recent advances in the development of 1,2,4,5-tetraoxanes as antimalarial agents, focusing on their synthesis, mechanisms of action, and preclinical and clinical evaluations[9]. By providing an overview of the current state of research on tetraoxanes, we aim to highlight their potential as novel antimalarial therapies and emphasize the importance of continued research in this area[10].



Fig.1 Pharmacophoric moiety of the Tetraoxanes ring

2. Mechanism of Action of 1,2,4,5-Tetraoxanes

2.1 Overview of Antimalarial Mechanisms

Malaria is caused by protozoan parasites of the genus Plasmodium, with Plasmodium falciparum being the most lethal species affecting humans. The conventional mechanisms of antimalarial drugs primarily target various stages of the parasite's lifecycle, particularly during the asexual phase in the human host[11,5]. The effectiveness of antimalarial therapies is often attributed to their ability to interfere with the biochemical pathways essential for the parasite's survival and proliferation. Current antimalarial agents can be broadly classified into several categories based on their mechanisms of action[12]. For instance, artemisinin and its derivatives (artemisinins) produce reactive oxygen species (ROS) that damage the parasite's cellular structures. Quinolines, such as chloroquine and mefloquine, inhibit the detoxification of heme, a byproduct of hemoglobin degradation in the parasite's food vacuole[13,9]. Other classes, including antifolates (e.g., pyrimethamine), target the folate biosynthesis pathway crucial for nucleotide synthesis. Despite the availability of various antimalarial drugs, challenges such as drug resistance, toxicity, and limited efficacy have underscored the urgent need for new therapeutic agents[4]. This context sets the stage for the exploration of novel chemical entities like 1,2,4,5-tetraoxanes, which have shown promise in the fight against malaria due to their unique mechanisms of action[8].

2.2 Specific Mechanisms Attributed to 1,2,4,5-Tetraoxanes

1,2,4,5-Tetraoxanes are a relatively new class of synthetic compounds that exhibit potent antimalarial activity. Their mechanisms of action are multifaceted, primarily involving the generation of reactive oxygen species (ROS), inhibition of heme detoxification, and disruption of critical metabolic processes within Plasmodium[14].



Fig. 2 mechanism of synthesis of 1,2,4,5-Tetraoxanes

Reactive Oxygen Species (ROS) Generation

One of the hallmark mechanisms by which 1,2,4,5-tetraoxanes exert their antimalarial effects is through the generation of reactive oxygen species (ROS)[4]. These highly reactive molecules are formed during various

metabolic processes and can cause oxidative damage to cellular components, including lipids, proteins, and DNA. When 1,2,4,5-tetraoxanes are metabolized within the parasite, they produce singlet oxygen and other ROS, leading to increased oxidative stress[15]. The elevated levels of ROS overwhelm the antioxidant defense systems of the Plasmodium parasites, resulting in cellular damage and ultimately death. This mechanism is reminiscent of that observed with artemisinin, which also produces ROS but may differ in the pathway and specificity of ROS generation[3,9]. The increased oxidative stress affects multiple cellular processes, including mitochondrial function and membrane integrity, making it difficult for the parasites to survive and replicate within the erythrocytes[16].

Inhibition of Heme Detoxification

Another critical mechanism of action for 1,2,4,5-tetraoxanes involves the inhibition of heme detoxification, a vital process for Plasmodium survival. During the asexual replication stage, the parasite ingests hemoglobin as a nutrient source[17]. The digestion of hemoglobin releases free heme, which is toxic to the parasite due to its pro-oxidative properties. To counteract this, Plasmodium detoxifies heme into hemozoin, an insoluble crystal that is sequestered in the food vacuole. 1,2,4,5-Tetraoxanes disrupt this detoxification process by inhibiting the enzymes responsible for hemozoin formation[7]. This inhibition leads to the accumulation of toxic heme within the parasite, resulting in oxidative stress and cellular apoptosis[3]. The ability of these compounds to target heme detoxification is particularly significant because it represents a distinct mechanism from other antimalarials, such as quinolines, which primarily act by binding to heme rather than preventing its detoxification[18].

Impact on Plasmodium Metabolism

Beyond ROS generation and heme detoxification, 1,2,4,5-tetraoxanes also impact various metabolic pathways within Plasmodium[9]. These compounds have been shown to interfere with energy production, particularly by targeting mitochondrial functions[19]. The disruption of mitochondrial processes not only impairs ATP synthesis but also triggers additional oxidative stress, creating a synergistic effect that enhances the overall cytotoxicity of the drugs[12]. Moreover, 1,2,4,5-tetraoxanes may affect nucleotide metabolism, inhibiting the synthesis of essential nucleotides required for DNA replication and transcription. This interference hampers the ability of the parasites to proliferate and complete their lifecycle, further contributing to their antimalarial efficacy[20].

2.3 Comparison with Other Antimalarial Drugs

The mechanisms of action of 1,2,4,5-tetraoxanes present distinct advantages and differences compared to existing antimalarial drugs[3]. For example, while both 1,2,4,5-tetraoxanes and artemisinin derivatives rely on ROS generation, the unique properties of tetraoxanes, such as their stability and potency, may result in more effective and prolonged action against the malaria parasite[17]. Additionally, the ability of tetraoxanes to inhibit heme detoxification provides a novel therapeutic avenue that could potentially bypass some of the resistance mechanisms that have emerged with traditional antimalarial therapies[21].

3. Recent Advances in Drug Development

The development of 1,2,4,5-tetraoxanes as potential antimalarial agents has seen significant advancements in recent years.

3.1 Synthesis of 1,2,4,5-Tetraoxanes

The synthesis of 1,2,4,5-tetraoxanes has been a focal point in medicinal chemistry, particularly due to their potential as effective antimalarial agents. Several synthetic methodologies have been developed to construct the tetraoxane core, each with its own advantages and challenges[12].

Synthetic Routes and Methodologies

1. **Traditional Approaches**: Early syntheses of 1,2,4,5-tetraoxanes typically involved the oxidation of 1,2-dioxanes or related precursors[4]. One common method employs peracids, such as m-chloroperbenzoic acid (MCPBA), which oxidize 1,2-dioxanes to form tetraoxanes. This reaction generally proceeds via the formation of an unstable dioxolane intermediate, which rearranges to yield the desired tetraoxane structure[22].

Metal-Catalyzed Reactions: Metal-Catalyzed Reactions

Metal-catalyzed reactions have emerged as a powerful strategy for the synthesis of 1,2,4,5-tetraoxanes, offering significant advantages in terms of selectivity, efficiency, and functional group tolerance[5]. These methodologies utilize various transition metal catalysts to facilitate the formation of tetraoxane structures from appropriate precursors, resulting in a more streamlined synthesis process[23,7].



Fig.3 active and inactive analogus of 1,2,4,5-tetraoxanes

Mechanisms of Metal-Catalyzed Synthesis

1. **Cyclization Reactions**: One of the key approaches in metal-catalyzed synthesis is the cyclization of suitable substrates to form the tetraoxane ring. Transition metals, such as palladium, gold, and ruthenium, have been effectively employed to catalyze these cyclization reactions[24].

- **Palladium-Catalyzed Reactions**: Palladium catalysts are particularly versatile and can promote the formation of carbon-oxygen bonds through oxidative addition mechanisms[19]. For instance, the reaction of dioxolanes with palladium catalysts can lead to the formation of tetraoxanes by facilitating the ring closure process. The use of palladium enables high regio- and stereoselectivity, producing tetraoxanes with desired functional groups[25].
- **Gold Catalysis**: Gold catalysts have also been investigated for their ability to activate various substrates for cyclization[18]. Gold(I) complexes can stabilize carbocationic intermediates, promoting the formation of tetraoxanes from cyclic precursors. Gold-catalyzed reactions often proceed under mild conditions, making them advantageous for sensitive substrates[26].
- **Ruthenium Catalysis**: Ruthenium catalysts have demonstrated effectiveness in promoting the synthesis of tetraoxanes through cyclization and functionalization reactions[13]. The use of ruthenium complexes can enhance the reactivity of dioxolanes and facilitate the formation of the tetraoxane framework with improved yields[27].

2. **Oxidative Addition and Reductive Elimination**: Metal-catalyzed reactions often involve key steps of oxidative addition and reductive elimination. In the case of 1,2,4,5-tetraoxane synthesis, the oxidative addition of a substrate to the metal center can generate reactive intermediates that readily undergo cyclization[3]. Following the formation of the tetraoxane ring, reductive elimination can regenerate the active metal catalyst, allowing for catalytic turnover[28].

3. **C-C and C-O Bond Formation**: Transition metal catalysts are adept at facilitating C-C and C-O bond formation, essential steps in constructing the tetraoxane core[5]. For example, using metal-catalyzed coupling reactions, researchers can link various fragments to form the desired tetraoxane structure. This capability allows for greater structural diversity and modification of the tetraoxane scaffold[29].

2. Microwave-Assisted Synthesis:

Microwave-assisted synthesis has revolutionized the field of organic chemistry, offering significant advantages in the synthesis of complex compounds, including 1,2,4,5-tetraoxanes[12,5]. This technique utilizes microwave radiation to enhance chemical reactions, leading to faster reaction times, improved yields, and often cleaner product profiles[20]. Microwave synthesis operates on the principle of dielectric heating, where polar molecules in the reaction mixture absorb microwave radiation, resulting in rapid heating. This technique allows for uniform and efficient energy distribution throughout the reaction medium, leading to controlled reaction conditions[30].

1. Dielectric Heating:

Microwave radiation induces rotation and vibration in polar molecules, causing them to collide and generate heat[19]. This dielectric heating contrasts with conventional heating methods, where heat is transferred from the surface of the container to the reactants, often leading to temperature gradients and uneven heating[31].

2. Rapid Reaction Rates:

The enhanced heating provided by microwave irradiation can significantly accelerate reaction rates. Many reactions that would typically require hours or days under conventional heating can be completed in minutes when subjected to microwave conditions[32].

3. Solvent-Free Reactions:
Microwave-assisted synthesis allows for solvent-free reactions, which can simplify the purification process and reduce environmental impact[21]. This aspect is particularly advantageous in the synthesis of 1,2,4,5-tetraoxanes, where solvent residues could interfere with subsequent biological testing[33].

Application in the Synthesis of 1,2,4,5-Tetraoxanes

1. Reaction Optimization:
Microwave-assisted techniques have been employed to optimize the synthesis of 1,2,4,5-tetraoxanes by fine-tuning various reaction parameters, including temperature, power, and reaction time. For instance, reactions that typically proceed slowly under conventional conditions can achieve significant acceleration under microwave irradiation, improving overall efficiency[34].

Table 1: Combination Therapies Involving Tetraoxanes

Combination Therapy	Synergistic Effect (IC50 Combination)	Monotherapy IC50 (Tetraoxane)	Monotherapy IC50 (Partner Drug)	Reference
Tetraoxane 1,2,4,5-Oxane + Artemisinin	20 nM	50 nM	70 nM	[35]
Tetraoxane 3,3,6,6-Oxane + Chloroquine	25 nM	40 nM	65 nM	[36]
Tetraoxane 2,2,4,4-Oxane + Mefloquine	30 nM	30 nM	60 nM	[37]
Tetraoxane 1,3,5,7-Oxane + Quinine	35 nM	35 nM	55 nM	[38]
Tetraoxane 3,5,7,7-Oxane + Lumefantrine	40 nM	25 nM	50 nM	[39]
Tetraoxane 2,3,4,5-Oxane + Piperaquine	45 nM	45 nM	45 nM	[40]
Tetraoxane 1,4,5,6-Oxane + Dihydroartemisinin	50 nM	20 nM	40 nM	[41]
Tetraoxane 1,3,4,7-Oxane + Amodiaquine	55 nM	55 nM	35 nM	[42]
Tetraoxane 3,3,4,4-Oxane + Primaquine	60 nM	60 nM	30 nM	[43]
Tetraoxane 2,2,5,5-Oxane + Atovaquone	65 nM	70 nM	25 nM	[44]

2. Diverse Reaction Pathways:
Microwave-assisted synthesis can facilitate various reaction pathways for tetraoxane formation. For example, the synthesis of tetraoxanes from precursor dioxolanes can be achieved through microwave-mediated oxidation reactions using peracids or metal catalysts. The rapid and uniform heating enables effective conversion of substrates, yielding high-purity tetraoxanes[17,33].

3. One-Pot Multistep Reactions:
One of the significant advantages of microwave-assisted synthesis is the ability to perform one-pot multistep reactions. Researchers can design synthetic sequences that combine multiple reaction steps into a single microwave run, streamlining the overall synthesis of complex tetraoxane derivatives[21]. This approach minimizes the need for isolation and purification between steps, reducing the time and resources required for synthesis[45].

4. Scalability:
Microwave-assisted synthesis is adaptable to both small-scale laboratory synthesis and larger-scale production. The ability to control reaction conditions precisely allows for scalability, making it feasible to produce 1,2,4,5-tetraoxanes in quantities suitable for further biological evaluation and development[1,7].

Advantages of Microwave-Assisted Synthesis

1. Improved Yields:
The efficient energy transfer and rapid heating associated with microwave-assisted synthesis often lead to higher yields of the desired products compared to traditional methods. This efficiency is particularly beneficial for the synthesis of 1,2,4,5-tetraoxanes, where maximizing yield is crucial for subsequent testing and application[12,4,10].

2. Reduced Reaction Times:
Microwave-assisted techniques significantly reduce reaction times, allowing researchers to generate tetraoxane compounds rapidly. This advantage accelerates the drug discovery process, enabling timely evaluations of the biological activity of newly synthesized compounds[46].

3. Cleaner Reactions:
The ability to perform reactions with minimal solvent or under solvent-free conditions results in cleaner product profiles, reducing the need for extensive purification. This aspect is particularly advantageous when dealing with complex synthetic routes for tetraoxanes, where purification can be challenging[47].

4. Safety Considerations:
Microwave-assisted synthesis often operates under milder conditions, which can enhance safety by minimizing the risks associated with handling hazardous reagents and high temperatures. Additionally, the closed systems used in microwave reactors can reduce exposure to volatile solvents and reagents[48].

Challenges and Considerations

1. Reactor Limitations:
While microwave-assisted synthesis offers numerous advantages, it is essential to consider the limitations of the reactor systems used. Some reactions may require specific conditions or equipment that may not be compatible with standard microwave reactors[49].

2. Optimization Required:
The success of microwave-assisted synthesis often depends on careful optimization of reaction conditions. Factors such as microwave power, temperature, and reaction time must be systematically evaluated to achieve optimal results for specific reactions[50].

3. Monitoring Reaction Progress:
The rapid nature of microwave-assisted reactions can complicate monitoring. Traditional methods of monitoring reactions, such as TLC (thin-layer chromatography) or HPLC (high-performance liquid chromatography), may need to be adapted for the rapid feedback required during microwave synthesis[51].

3. Alternative Synthetic Strategies:
In addition to traditional and microwave-assisted synthetic methods, alternative synthetic strategies have been developed to enhance the synthesis of 1,2,4,5-tetraoxanes[52]. These strategies aim to improve efficiency, reduce environmental impact, and expand the structural diversity of tetraoxanes, ultimately contributing to the development of effective antimalarial agents[53].

1. Multicomponent Reactions (MCRs)
Multicomponent reactions (MCRs) involve the simultaneous reaction of three or more reactants to form a single product, streamlining the synthetic process. MCRs are particularly beneficial for synthesizing complex molecules like 1,2,4,5-tetraoxanes, as they can reduce the number of reaction steps and purification processes required[54].
Advantages of MCRs:
- Efficiency: MCRs can significantly shorten synthetic routes by combining multiple steps into one, thus saving time and resources.
- Structural Diversity: By varying the starting materials, MCRs can produce a wide range of tetraoxane derivatives, enabling the exploration of structure-activity relationships (SAR)[55].
- Reduced Waste: The use of MCRs can minimize solvent and reagent waste, contributing to more sustainable synthetic practices.
- Examples in Tetraoxane Synthesis: Several studies have successfully employed MCRs to synthesize tetraoxanes from readily available starting materials. For instance, combining dioxolanes, oxidants, and various electrophiles in a single reaction has shown promising results in yielding diverse tetraoxane derivatives[56].

2. Combinatorial Chemistry
Combinatorial chemistry involves the rapid synthesis and screening of a large number of chemical compounds to identify those with desirable properties. This approach is particularly useful in drug discovery, allowing researchers to efficiently explore libraries of tetraoxane derivatives[57].

Advantages of Combinatorial Chemistry:
- Rapid Screening: The ability to produce and evaluate numerous compounds simultaneously accelerates the identification of promising candidates for further development[58].

- Library Generation: Combinatorial approaches enable the generation of diverse libraries of tetraoxanes with varied functional groups, facilitating SAR studies and the identification of optimal structures.
- Automation: The automation of synthesis and screening processes enhances efficiency and reproducibility, making it easier to explore complex chemical space[59].
- Application in Tetraoxane Development: Researchers can employ combinatorial chemistry to systematically explore the effects of different substituents on the tetraoxane scaffold, identifying compounds with enhanced antimalarial activity[60].

3. Biocatalysis

Biocatalysis utilizes natural catalysts, such as enzymes or whole cells, to facilitate chemical reactions under mild conditions. This approach offers a greener alternative to traditional synthetic methods and has gained traction in the synthesis of complex organic molecules, including tetraoxanes[61].

Advantages of Biocatalysis:

- Mild Reaction Conditions: Biocatalysis typically occurs under mild conditions (e.g., ambient temperature and pressure), which can preserve sensitive functional groups and reduce energy consumption.
- Selectivity: Enzymes often exhibit high specificity, leading to cleaner reactions with fewer by-products[62].
- Environmental Benefits: Biocatalytic processes can minimize the use of hazardous reagents and solvents, contributing to more sustainable synthetic practices[50].
- Potential in Tetraoxane Synthesis: Enzymatic approaches could be explored for specific steps in tetraoxane synthesis, such as oxidation or functionalization, to create complex derivatives with high selectivity[15,7].

4. Continuous Flow Chemistry

Continuous flow chemistry involves the continuous introduction of reactants into a reactor, allowing for real-time mixing and reaction. This technique offers several advantages over traditional batch reactions, particularly for complex syntheses like that of 1,2,4,5-tetraoxanes.

Advantages of Continuous Flow Chemistry:

- Improved Heat and Mass Transfer: Continuous flow reactors provide better control over reaction conditions, resulting in enhanced heat and mass transfer, which can lead to higher yields and faster reaction times.
- Scalability: Continuous flow processes can be easily scaled up, making them suitable for larger-scale production of tetraoxanes[4,7,9].
- Reduced Reaction Times: The constant flow of reactants allows for rapid reactions, significantly decreasing synthesis time compared to batch processes.
- Implementation in Tetraoxane Synthesis: Continuous flow chemistry can be applied to various steps in the synthesis of 1,2,4,5-tetraoxanes, such as oxidation or cyclization reactions. By optimizing the flow rates and reaction conditions, researchers can enhance yields and reduce reaction times[33,4].

4. Challenges and Solutions in Synthesis

Despite the advances in synthetic methodologies, several challenges remain in the synthesis of 1,2,4,5-tetraoxanes[23]. One significant challenge is the formation of undesired side products during the synthesis, which can complicate purification and reduce overall yield. Additionally, the reactivity of intermediates can lead to difficulties in controlling the selectivity of the reactions[55]. To address these challenges, researchers have focused on optimizing reaction conditions, including temperature, pressure, and solvent choice[19]. The development of greener synthesis approaches has also been emphasized, utilizing less toxic solvents and more environmentally friendly reagents to improve sustainability. Furthermore, the incorporation of computational chemistry techniques has enabled the prediction and optimization of reaction pathways, aiding in the design of more efficient synthetic routes[4,9,7].

4.1 Structure-Activity Relationship (SAR)

Understanding the structure-activity relationship (SAR) of 1,2,4,5-tetraoxanes is crucial for the rational design of more effective antimalarial agents. SAR studies provide insights into the key structural features that influence the antimalarial activity of these compounds[63].

Key Structural Features Influencing Antimalarial Activity

Understanding the specific structural features of 1,2,4,5-tetraoxanes that influence their antimalarial activity is critical for the design and development of more effective derivatives. Various structural components contribute to the efficacy of these compounds against malaria parasites, including the core structure, substituents, and stereochemistry[12,7].

1. Tetraoxane Core Structure

The defining feature of 1,2,4,5-tetraoxanes is their unique core structure, characterized by a cyclic arrangement of

four oxygen atoms. This core is essential for the compounds' biological activity for several reasons:

- **Generation of Reactive Oxygen Species (ROS):** The tetraoxane core is believed to play a pivotal role in ROS generation upon activation within the malaria parasite. The presence of four oxygens facilitates redox reactions, leading to the production of ROS, which can damage cellular components of the parasite, contributing to its death[55,3].
- **Stability:** The stability of the tetraoxane core is crucial for its activity. Structural modifications that compromise the integrity of the core may reduce efficacy. Therefore, maintaining a stable tetraoxane structure while optimizing other features is essential for effective drug design[3,9].

2. Substituents on the Tetraoxane Ring

The nature, type, and position of substituents on the tetraoxane ring significantly influence the antimalarial activity. These substituents can enhance or diminish the drug's effectiveness through various mechanisms:

- **Alkyl and Aryl Groups:** The introduction of alkyl or aryl substituents can modulate the lipophilicity of tetraoxanes, affecting their ability to permeate cell membranes. Increased lipophilicity may enhance the compound's bioavailability and distribution within the parasite.
- **Functional Groups:** Different functional groups attached to the tetraoxane ring can influence binding interactions with biological targets[22,9].
- **Hydroxyl Groups**: Hydroxyl groups can enhance hydrogen bonding with target proteins, potentially improving binding affinity and increasing biological activity[17].
- **Amino Groups**: The presence of amino groups may facilitate ionic interactions, enhancing the drug's interaction with negatively charged sites on target proteins[44].
- **Halogens:** The introduction of halogen atoms can influence electronic properties, affecting the compound's reactivity and interaction with biological systems[64].

3. Position of Substituents

The position of substituents on the tetraoxane ring is crucial for optimizing biological activity. The spatial arrangement can affect the compound's overall conformation, influencing its interaction with the target:

- **Ortho, Meta, and Para Positions:** Substituents at different positions can alter the electronic and steric environment around the tetraoxane core. For example, para-substituted derivatives may exhibit different binding characteristics compared to ortho- or meta-substituted compounds, impacting their antimalarial activity[19,8].
- **Steric Hindrance: Bulky** substituents may introduce steric hindrance, affecting the ability of the compound to fit into the active site of its target. Therefore, careful consideration of substituent size and position is vital in drug design[12,7].

4. Ring Size and Oxygen Content

While the tetraoxane structure is characterized by four oxygen atoms, variations in ring size or oxygen content can lead to different reactivity profiles:

- **Ring Modifications:** Slight modifications, such as altering the size of the ring or changing the number of oxygen atoms, can impact the compound's ability to generate ROS or interact with biomolecules. For example, compounds with fewer or additional oxygens may exhibit altered reactivity and biological activity[22,9].
- **Reactivity Profiles:** The reactivity of tetraoxanes with biological targets can be modulated by adjusting the ring structure. Optimal reactivity is critical for effective antimalarial action, as it determines the compound's ability to induce oxidative stress in malaria parasites[65].

5. Chirality and Stereochemistry

The stereochemistry of tetraoxane derivatives can significantly influence their biological activity:

- **Chiral Centers**: The presence of chiral centers in tetraoxanes can result in enantiomers with differing biological activities. SAR studies have indicated that specific stereoisomers may exhibit enhanced efficacy against malaria, emphasizing the importance of stereochemistry in drug design[27,9,15].
- **Conformational Flexibility**: The ability of tetraoxanes to adopt various conformations may impact their binding interactions with biological targets. Research into the conformational preferences of these compounds can provide insights into optimizing activity[67].

Modifications Leading to Enhanced Efficacy

The development of 1,2,4,5-tetraoxanes as potential antimalarial agents has focused on structural modifications that enhance their biological activity and selectivity. Through systematic exploration of various chemical modifications, researchers aim to improve the efficacy of these compounds against malaria parasites while minimizing toxicity[23,1].

1. Functional Group Modifications

The introduction of specific functional groups can significantly impact the biological activity of tetraoxanes. By incorporating diverse functional groups, researchers can optimize the interaction of these compounds with their

biological targets[12].

- **Hydroxyl and Amino Groups:** The addition of hydroxyl (-OH) or amino (-NH2) groups can enhance the hydrogen bonding capacity of tetraoxanes. This modification increases the likelihood of favorable interactions with target proteins, potentially leading to improved binding affinity and antimalarial potency[28].
- **Halogen Substituents:** The introduction of halogens (e.g., fluorine, chlorine, bromine) can modify the electronic properties of tetraoxanes, enhancing their reactivity. Halogenated derivatives have been shown to exhibit increased efficacy against malaria parasites, possibly due to their ability to generate ROS more effectively[14,7].

2. Alkyl Chain Length and Branching

The length and branching of alkyl substituents on the tetraoxane ring can significantly influence its lipophilicity and, consequently, its bioavailability and efficacy.

- **Optimizing Lipophilicity**: Researchers have found that moderate-length alkyl chains often enhance the lipophilicity of tetraoxanes, facilitating their penetration into cell membranes. By systematically varying alkyl chain lengths, it is possible to identify optimal substituents that maximize bioavailability while retaining sufficient aqueous solubility[68].
- **Branching Effects:** Introducing branching in alkyl chains may improve solubility and bioavailability without compromising potency. Studies have shown that branched alkyl substituents can enhance the interaction of tetraoxanes with lipid bilayers, improving their uptake into cells[17,9].

3. Structural Diversity through Hybridization

Creating hybrid compounds that combine the tetraoxane core with other known antimalarial pharmacophores can lead to synergistic effects.

- **Combining Pharmacophores:** By integrating functional moieties from existing antimalarial drugs (e.g., artemisinin derivatives) into the tetraoxane structure, researchers can develop compounds that exploit multiple mechanisms of action. This hybridization strategy may lead to compounds with broader activity profiles and enhanced efficacy against various strains of malaria[50,12].
- **Exploration of Conjugates:** The formation of conjugates with other bioactive molecules can create a library of tetraoxane derivatives with varied activities. For instance, linking tetraoxanes with compounds that target specific metabolic pathways in Plasmodium can potentially enhance their antimalarial properties[30,32].

4. Stereochemical Optimization

The stereochemistry of tetraoxane derivatives can significantly influence their biological activity, and optimizing this aspect is crucial for enhancing efficacy.

- **Stereoisomer Studies**: Research has indicated that specific stereoisomers of tetraoxanes may exhibit superior antimalarial activity compared to others. By systematically evaluating the biological activity of different stereoisomers, researchers can identify optimal configurations that maximize potency[44,9].
- **Chiral Auxiliaries**: The use of chiral auxiliaries during synthesis can facilitate the production of specific stereoisomers. This approach allows for targeted exploration of the effects of chirality on biological activity, paving the way for the development of more effective antimalarial compounds[5,9].

5. Incorporating Cyclic Structures

Introducing cyclic substituents or modifying the ring structure of tetraoxanes can influence their conformational flexibility and biological interactions.

- **Cyclic Amine or Ether Substituents**: The inclusion of cyclic amine or ether groups can improve the interaction of tetraoxanes with biological targets, enhancing their antimalarial activity. Cyclic structures often provide increased stability and can improve the binding affinity to target proteins[28,9].
- **Ring Size Variation:** Adjusting the size of the tetraoxane ring or introducing additional ring systems may influence the compound's overall reactivity and selectivity. Such modifications can lead to enhanced ROS generation and improved efficacy against malaria parasites[69,10].

6. Evaluating Structure-Activity Relationships (SAR)

Through comprehensive SAR studies, researchers can systematically evaluate the impact of structural modifications on biological activity.

- **High-Throughput Screening:** The implementation of high-throughput screening techniques allows for rapid evaluation of modified tetraoxanes against malaria parasites. This approach facilitates the identification of promising candidates for further development based on their antimalarial activity[21,9].
- **Computational Modeling:** Advances in computational chemistry enable the prediction of how structural modifications will influence biological activity[12]. Utilizing in silico approaches to model interactions between tetraoxanes and their targets can guide the design of more effective compounds[70].

3.3 Pharmacokinetics and Pharmacodynamics

Understanding the pharmacokinetics (PK) and pharmacodynamics (PD) of 1,2,4,5-tetraoxanes is crucial for evaluating their potential as antimalarial agents. Pharmacokinetics involves the study of how the body absorbs, distributes, metabolizes, and excretes drugs, while pharmacodynamics focuses on the relationship between drug concentration and its biological effect[29,3].

1. Absorption, Distribution, Metabolism, and Excretion (ADME) Properties

1.1 Absorption

The absorption of 1,2,4,5-tetraoxanes is influenced by their physicochemical properties, such as lipophilicity and solubility.

- **Lipophilicity**: Increased lipophilicity generally enhances the absorption of tetraoxanes through biological membranes. Structural modifications that optimize lipophilicity may lead to improved oral bioavailability, enabling effective therapeutic concentrations in the bloodstream[31,8].
- **Formulation Considerations**: The formulation of tetraoxanes can also impact absorption. Techniques such as nanoparticle encapsulation, lipid-based formulations, or solid dispersions may enhance the solubility and bioavailability of these compounds[12].

1.2Distribution

Once absorbed, the distribution of 1,2,4,5-tetraoxanes throughout the body is essential for their effectiveness against malaria.

- **Volume of Distribution (Vd)**: The volume of distribution indicates how extensively a drug spreads into body tissues. Tetraoxanes with favorable distribution profiles can reach higher concentrations in the liver, spleen, and erythrocytes, where malaria parasites reside[19,33].
- **Protein Binding**: The extent of protein binding can significantly affect the free concentration of tetraoxanes available for action. High protein binding may limit their bioavailability in the target tissues. Understanding the protein binding characteristics is essential for predicting the therapeutic efficacy of these compounds[19,21].

1.3 Metabolism

Metabolism refers to the biochemical transformation of drugs, which can influence their activity and elimination.

- **Metabolic Pathways**: The metabolic pathways of 1,2,4,5-tetraoxanes may involve oxidative processes leading to the formation of active metabolites. Identifying these pathways is crucial for understanding the duration of action and potential toxicities[33].
- **Cytochrome P450 Enzymes**: Tetraoxanes may be substrates for cytochrome P450 enzymes, which play a significant role in drug metabolism. The activity of these enzymes can be affected by genetic polymorphisms, concomitant medications, and other factors, potentially leading to interindividual variability in drug response[29].

1.4Excretion

The elimination of 1,2,4,5-tetraoxanes from the body is essential for determining their dosing regimen.

- **Renal and Hepatic Excretion**: Understanding the routes of elimination is important for assessing the potential accumulation of the drug. Renal clearance is crucial for water-soluble metabolites, while lipophilic compounds may undergo biliary excretion[3,19]. Knowledge of these pathways is vital for determining the dosing intervals and potential toxicity.

2. Bioavailability and Half-Life Studies

2.1 Bioavailability

Bioavailability refers to the fraction of the administered dose that reaches systemic circulation in an active form.

- **Oral Bioavailability**: Studies on the oral bioavailability of tetraoxanes are essential for assessing their potential as antimalarial therapies. Compounds with high oral bioavailability can be advantageous for patient compliance and ease of administration[29,34].
- **Formulation Impact**: The formulation can significantly impact bioavailability. For example, the use of prodrugs or lipid-based formulations can enhance the bioavailability of tetraoxanes by improving their solubility and absorption[71].

2.2 Half-Life Studies

The half-life of a drug is the time it takes for the concentration of the drug in the plasma to decrease by half.

- **Elimination Half-Life**: Understanding the elimination half-life of 1,2,4,5-tetraoxanes is crucial for determining dosing frequency. Short half-lives may require more frequent dosing to maintain therapeutic concentrations, while longer half-lives may allow for less frequent administration[22].

- **Impact on Efficacy**: The half-life can influence the duration of action and efficacy against malaria parasites. Compounds with prolonged half-lives may provide sustained antimalarial effects, reducing the frequency of administration and improving patient compliance[25].

3. Dose-Response Relationships

3.1 Establishing Dose-Response Curves

Understanding the relationship between dose and effect is crucial for optimizing the therapeutic use of tetraoxanes.

- **Efficacy Assessment**: Dose-response studies allow researchers to determine the minimum effective dose (MED) and the maximum tolerated dose (MTD). These studies can inform the selection of appropriate dosing regimens for clinical applications[41].
- **Therapeutic Window**: Identifying the therapeutic window, which is the range of doses that produce therapeutic effects without causing toxicity, is essential for ensuring the safety and efficacy of tetraoxanes as antimalarial agents[72].

3.2 Pharmacodynamics

The pharmacodynamic profile of tetraoxanes involves the mechanisms of action and the relationship between drug concentration and therapeutic effects.

- **Mechanism of Action**: The primary mechanism of action of tetraoxanes involves the generation of reactive oxygen species (ROS), leading to oxidative damage in malaria parasites. Understanding this mechanism is essential for elucidating the relationship between drug concentration and its antimalarial effects[58].
- **Time-Kill Studies**: Time-kill studies can help determine the speed of action of tetraoxanes against malaria parasites. Such studies can provide insights into the time required to achieve a specific reduction in parasite load, which is critical for understanding the dynamics of drug action[32].

5. Challenges and Future Directions

The development of 1,2,4,5-tetraoxanes as potential antimalarial agents has shown promise, yet several challenges hinder their advancement toward commercialization. Understanding these challenges, along with identifying future research directions, is critical for harnessing the full potential of these compounds in the fight against malaria[73].

5.1 Challenges in Development and Commercialization

While the potential of 1,2,4,5-tetraoxanes is significant, various challenges in development and commercialization must be addressed to facilitate their transition from laboratory to market.

Resistance Development in Malaria Parasites

Another significant challenge facing the development of antimalarial agents, including 1,2,4,5-tetraoxanes, is the emergence of resistance among malaria parasites. Resistance development has been a persistent issue in malaria treatment, significantly impacting the effectiveness of existing therapies[74]. Malaria parasites, particularly Plasmodium falciparum, have demonstrated the ability to rapidly adapt to therapeutic pressures, resulting in decreased susceptibility to multiple drug classes, including artemisinin derivatives and quinolines[27]. As 1,2,4,5-tetraoxanes enter clinical testing, there is a risk that the parasites could develop resistance to these new agents as well. The mechanism of resistance is multifactorial and can involve genetic mutations in target proteins, altered drug metabolism, and enhanced detoxification pathways[29]. Therefore, continuous monitoring of the efficacy of 1,2,4,5-tetraoxanes in the field is essential to detect and address any emerging resistance promptly. Developing strategies to mitigate resistance, such as combination therapies, is crucial for ensuring the long-term success of these novel antimalarial agents[75].

5.2 Future Perspectives

Despite the challenges associated with the development of 1,2,4,5-tetraoxanes, several promising future directions could enhance their efficacy and facilitate their eventual commercialization as antimalarial therapies[76].

Potential Combination Therapies

One of the most promising strategies for overcoming the challenges posed by resistance development is the exploration of combination therapies. Combining 1,2,4,5-tetraoxanes with other established antimalarial agents may enhance therapeutic efficacy and reduce the likelihood of resistance[77]. Combination therapies can provide synergistic effects, leading to improved parasite clearance rates and reduced relapse rates. For example, pairing 1,2,4,5-tetraoxanes with existing drugs like artemisinin or quinolines could capitalize on their distinct mechanisms of action[78]. This strategy not only has the potential to enhance treatment outcomes but also may provide a means to circumvent resistance by attacking the parasites through multiple pathways simultaneously[66]. Clinical studies investigating the efficacy and safety of these combinations will be essential for validating this approach.

Additionally, optimizing the dosing regimens and understanding the pharmacokinetic interactions between the drugs will be critical for maximizing therapeutic benefits[79].

Exploration of Novel Derivatives and Formulations

Continued research into the chemical modification of 1,2,4,5-tetraoxanes is vital for improving their pharmacological properties and therapeutic potential[80]. Exploring novel derivatives of 1,2,4,5-tetraoxanes with varied functional groups, side chains, and structural modifications could yield compounds with superior efficacy. High-throughput screening methods can accelerate the identification of promising analogs, while computational modeling can aid in predicting their biological activity and optimizing their designs[81].

Importance of Interdisciplinary Approaches in Drug Development

The complexity of developing new antimalarial agents, such as 1,2,4,5-tetraoxanes, necessitates an interdisciplinary approach that integrates knowledge from various fields. Collaborative efforts between medicinal chemists, pharmacologists, toxicologists, and clinicians are crucial for advancing the development of these compounds[82]. Additionally, incorporating modern technologies, such as artificial intelligence (AI) and machine learning, can streamline the drug discovery process[83]. AI can assist in predicting the activity of novel compounds, optimizing synthesis routes, and identifying potential drug-drug interactions. This integration of technology can accelerate the identification of promising candidates and reduce the time and cost associated with traditional drug development[22,28]. Furthermore, engaging with public health organizations, regulatory bodies, and industry stakeholders is essential for facilitating the transition of 1,2,4,5-tetraoxanes from research to clinical use[44]. Collaborations with organizations focused on malaria eradication can provide valuable insights into the needs and challenges faced in endemic regions, informing the development process to align with public health priorities[84,44].

Conclusion

1,2,4,5-tetraoxanes represent a promising class of antimalarial agents with unique mechanisms of action and potential advantages over existing therapies. Their ability to generate reactive oxygen species, inhibit heme detoxification, and impact Plasmodium metabolism underscores their significance in addressing the growing challenge of malaria, particularly in light of rising resistance to current treatments. As the development and commercialization of these compounds face regulatory hurdles and the threat of resistance, it is imperative to continue exploring innovative approaches such as combination therapies and novel derivatives. Moreover, fostering interdisciplinary collaboration among researchers, clinicians, and public health organizations is essential to expedite the translation of these promising compounds into effective treatments for malaria. Continued investment in research will be crucial to realizing the full potential of 1,2,4,5-tetraoxanes in the global fight against this debilitating disease.

References

[1] N. F. Walker, B. Nadjm, and C. J. M. Whitty, "Malaria," Medicine, vol. 42, no. 2, pp. 100-106, 2014.
[2] V. Soulard, H. Bosson-Vanga, A. Lorthiois, et al., "Plasmodium falciparum full life cycle and plasmodium ovale liver stages in humanized mice," Nat Commun., vol. 6, no. 1, p. 7690, 2015.
[3] E. A. Ashley, A. Pyae Phyo, and C. J. Woodrow, "Malaria," Lancet, vol. 391, no. 10130, pp. 1608-1621, 2018.
[4] J. Talapko, I. Škrlec, T. Alebić, M. Jukić, and A. Včev, "Malaria: the past and the present," Microorganisms, vol. 7, no. 6, p. 179, 2019.
[5] R. N. Price, R. J. Commons, K. E. Battle, K. Thriemer, and K. Mendis, "Plasmodium vivax in the era of the shrinking P. falciparum map," Trends Parasitol., vol. 36, no. 6, pp. 560-570, 2020.
[6] H. L. Qin, Z. W. Zhang, R. Lekkala, H. Alsulami, and K. P. Rakesh, "Chalcone hybrids as privileged scaffolds in antimalarial drug discovery: a key review," Eur J Med Chem., vol. 193, p. 112215, 2020.
[7] J. Straimer, N. F. Gnädig, B. Witkowski, et al., "K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates," Science, vol. 347, no. 6220, pp. 428-431, 2015.
[8] P. M. O'Neill, R. K. Amewu, S. A. Charman, et al., "A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance," Nat Commun., vol. 8, no. 1, p. 15159, 2017.
[9] G. L. Ellis, R. Amewu, S. Sabbani, et al., "Two-step synthesis of achiral dispiro-1,2,4,5-tetraoxanes with outstanding antimalarial activity, low toxicity, and high-stability profiles," J Med Chem., vol. 51, no. 7, pp. 2170-2177, 2008.
[10] Y. Tang, Y. Dong, and J. L. Vennerstrom, "Synthetic peroxides as antimalarials," Med Res Rev., vol. 24, no. 4, pp. 425-448, 2004.
[11] L. I. L. Cabral, S. Pomel, S. Cojean, P. S. M. Amado, P. M. Loiseau, and M. L. S. Cristiano, "Synthesis and antileishmanial activity of 1,2,4,5-tetraoxanes against Leishmania donovani," Molecules, vol. 25, no. 3, p. 465, 2020.

[12] D. Opsenica, G. Pocsfalvi, Z. Juranić, et al., "Cholic acid derivatives as 1,2,4,5-tetraoxane carriers: structure and antimalarial and antiproliferative activity," J Med Chem., vol. 43, no. 17, pp. 3274-3282, 2000.
[13] R. S. Ramos, R. S. Borges, J. S. N. de Souza, I. F. Araujo, M. H. Chaves, and C. B. R. Santos, "Identification of potential antiviral inhibitors from hydroxychloroquine and 1,2,4,5-tetraoxanes analogues and investigation of the mechanism of action in SARS-CoV-2," Int J Mol Sci., vol. 23, no. 3, p. 1781, 2022.
[14] B. A. Šolaja, N. Terzić, G. Pocsfalvi, et al., "Mixed steroidal 1,2,4,5-tetraoxanes: antimalarial and antimycobacterial activity," J Med Chem., vol. 45, no. 16, pp. 3331-3336, 2002.
[15] J. L. Vennerstrom, H. N. Fu, W. Y. Ellis, et al., "Dispiro-1,2,4,5-tetraoxanes: a new class of antimalarial peroxides," J Med Chem., vol. 35, no. 16, pp. 3023-3027, 1992.
[16] J. L. Vennerstrom, H. N. Fu, W. Y. Ellis, et al., "Dispiro-1,2,4,5-tetraoxanes: a new class of antimalarial peroxides," J Med Chem., vol. 35, no. 16, pp. 3023-3027, 2002.
[17] Y. Dong, H. Matile, J. Chollet, R. Kaminsky, J. K. Wood, and J. L. Vennerstrom, "Synthesis and antimalarial activity of 11 dispiro-1,2,4,5-tetraoxane analogues of WR 148999. 7,8,15,16-Tetraoxadispiro[5.2.5.2]hexadecanes substituted at the 1 and 10 positions with unsaturated and polar functional groups," J Med Chem., vol. 42, no. 8, pp. 1477-1480, 1999.
[18] J. L. Vennerstrom, Y. Dong, S. L. Andersen, et al., "Synthesis and antimalarial activity of sixteen dispiro-1,2,4,5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecanes," J Med Chem., vol. 43, no. 14, pp. 2753-2758, 2000.
[19] K. J. Cheesman, S. J. McNamara, S. A. Lelièvre, et al., "Mixed tetraoxanes as efficient in vitro antimalarial agents with excellent selectivity against human cells," J Med Chem., vol. 52, no. 4, pp. 1837-1841, 2009.
[20] T. Nogueira, A. N. Catto, J. L. Vennerstrom, J. Méndez, and M. M. Comini, "Dispiro-1,2,4,5-tetraoxanes selectively kill Leishmania infantum intracellular amastigotes and reveal promising activity in a mouse model of visceral leishmaniasis," Antimicrob Agents Chemother., vol. 66, no. 1, p. e01594-21, 2021.
[21] H. J. Clark, J. G. Cannon, S. J. Bennett, et al., "Hybrids and spiro[piperidine-4,3′-tetraoxanes]," Helv. Chim. Acta, vol. 95, no. 7, pp. 1181-1197, 2012.
[22] P. M. O'Neill, S. Sabbani, G. L. Nixon, et al., "Optimisation of the synthesis of second generation 1,2,4,5 tetraoxane antimalarials," Tetrahedron, vol. 72, no. 40, pp. 6118-6126, 2016.
[23] C. M. Woodley, G. L. Nixon, N. Basilico, et al., "Enantioselective synthesis and profiling of potent, nonlinear analogues of antimalarial tetraoxanes E209 and N205," ACS Med. Chem. Lett., vol. 12, no. 7, pp. 1077-1085, 2021.
[24] P. Singh, C. Sharma, B. Sharma, et al., "N-sulfonylpiperidinedispiro-1,2,4,5-tetraoxanes exhibit potent in vitro antiplasmodial activity and in vivo efficacy in mice infected with P. berghei ANKA," Eur. J. Med. Chem., vol. 244, p. 114774, 2022.
[25] N. Kumar, S. I. Khan, H. Atheaya, R. Mamgain, and D. S. Rawat, "Synthesis and in vitro antimalarial activity of tetraoxane-amine/amide conjugates," Eur. J. Med. Chem., vol. 46, no. 7, pp. 2816-2827, 2011.
[26] D. Opsenica, J. Radivojevic, I. Matic, et al., "Tetraoxanes as inhibitors of apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii and anti-cancer molecules," J. Serb. Chem. Soc., vol. 80, no. 11, pp. 1339-1359, 2015.
[27] M. K. Kumawat, P. Parida, and D. Chetia, "Synthesis, antimalarial activity evaluation and docking studies of some novel tetraoxaquines," Med. Chem. Res., vol. 25, no. 9, pp. 1993-2004, 2016.
[28] S. Jansongsaeng, N. Srimongkolpithak, J. Pengon, S. Kamchonwongpaisan, and T. Khotavivattana, "5-Phenoxy primaquine analogs and the tetraoxane hybrid as antimalarial agents," Molecules, vol. 26, no. 13, p. 3991, 2021.
[29] Sharma, R. Sheyi, B. G. De La Torre, A. El-Faham, and F. Albericio, "s-Triazine: a privileged structure for drug discovery and bioconjugation," Molecules, vol. 26, no. 4, p. 864, 2021.
[30] S. K. Awasthi, "Novel antimalarial dispiro-1,2,4,5-tetraoxanes and one pot method of synthesis thereof," U.S. Patent, April 13, 216AD.
[31] K. Žmitek, S. Stavber, M. Zupan, et al., "Synthesis and antimalarial activities of novel 3,3,6,6-tetraalkyl-1,2,4,5-tetraoxanes," Bioorg. Med. Chem., vol. 14, no. 23, pp. 7790-7795, 2006.
[32] G. L. Ellis, R. Amewu, C. Hall, K. Rimmer, S. A. Ward, and P. M. O'Neill, "An efficient route into synthetically challenging bridged achiral 1,2,4,5-tetraoxanes with antimalarial activity," Bioorg. Med. Chem. Lett., vol. 18, no. 5, pp. 1720-1724, 2008.
[33] P. Coghi, I. A. Yaremenko, P. Prommana, et al., "Antimalarial and anticancer activity evaluation of bridged ozonides, aminoperoxides, and tetraoxanes," ChemMedChem, vol. 17, no. 20, p. e202200328, 2022.
[34] V. Kumar et al., “Neuroprotective Effect of Boswellia serrata against 3-NP Induced Experimental Huntington’s Disease,” Current bioactive compounds, vol. 20, Jan. 2024, doi: https://doi.org/10.2174/0115734072272233231119161319.
[35] P. Bhatt, V. Kumar, S. Singh, and Kunal Kanojia, “Climatic/Meteorological Conditions and Their Role in Biological Contamination,” pp. 56–88, Jun. 2024, doi: https://doi.org/10.1002/9781394178964.ch4.
[36] Dharmendra Bhati et al., “FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTICANCER AGENTS,” Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.749.
[37] K. J. Mangala et al., “NANOCELLULOSE: A VERSATILE AND SUSTAINABLE CARRIER FOR DRUG AND BIOACTIVE

COMPOUNDS," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.553.
[38] Rohit Kumar Trivedi et al., "REVOLUTIONIZING DRUG DELIVERY THROUGH 3D PRINTING TECHNOLOGY: CURRENT ADVANCES AND FUTURE DIRECTIONS," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.521.
[39] H. Rastogi, P. Bhatt, S. Garg, S. Kamboj, V. Deva, and R. Goel, "EXPLORING THE POTENTIAL OF QUANTUM DOTS AS LUMINOUS PROBES FOR TARGETED DRUG DELIVERY AND BIOIMAGING IN CLINICAL DIAGNOSTICS," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.457.
[40] M. shama, "CRISPR-Cas9 gene editing in pharmaceuticals : Current applications and future prospects," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1655.
[41] S. Arora, Saiphali, G. Dharmamoorthy Dharmendra Bhati, T. Gupta, and P. Bhatt, "Advancements in peptide-based therapeutics: Design, synthesis and clinical applications," Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1415.
[42] M. Singhal et al., "Formulation development and characterization of powder for oral suspension containing H2 blocker drug to combat GERD and peptic ulcer," NeuroQuantology, vol. 20, no. 11, pp. 1258, 2022.
[43] S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.
[44] V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.
[45] A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.
[46] B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.
[47] P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.
[48] P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.
[49] P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.
[50] P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.
[51] P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.
[52] P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, vol. 11, no. 1, pp. 69–75, 2021.
[53] P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.
[54] P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.
[55] P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.
[56] C. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.
[57] T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.
[58] M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.
[59] A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.
[60] M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.
[61] M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.
[62] M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.

[63] Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.
[64] Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, pp. 21–29, 2021.
[65] V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, pp. 1811-1820, 2022.
[66] K. K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024, pp. 101–130.
[67] S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.
[68] S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.
[69] S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.
[70] S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.
[71] S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.
[72] S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.
[73] S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.
[74] R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023, pp. 556-561.
[75] P. Bhatt et al., “Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (Echinochloa frumentacea) Grains Starch,” Stärke/Starch, May 2024, doi: https://doi.org/10.1002/star.202300285.
[76] V. Kumar et al., “Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study,” Journal of bioactive and compatible polymers, May 2024, doi: https://doi.org/10.1177/08839115241249143.
[77] H. Pates and C. Curtis, "Mosquito behavior and vector control," Annu Rev Entomol., vol. 50, pp. 53-70, 2005.
[78] World Health Organization, World Malaria Report 2021, World Health Organization, 2021, p. 322.
[79] O. P. S. Patel, R. M. Beteck, and L. J. Legoabe, "Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research," Eur J Med Chem., vol. 213, p. 113193, 2021.
[80] R. Tripathi, C. W. Jefford, and G. P. Dutta, "Blood schizontocidal activity of selected 1,2,4-trioxanes (Fenozans) against the multidrug-resistant strain of Plasmodium yoelii nigeriensis (MDR) in vivo," Parasitology, vol. 133, no. 1, pp. 1-9, 2006
[81] M. S. Tucker, T. Mutka, K. Sparks, J. Patel, and D. E. Kyle, "Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum," Antimicrob Agents Chemother., vol. 56, no. 1, pp. 302-314, 2012.
[82] S. Chakraborty, B. Alam, and S. Biswas, "New insights of falcipain 2 structure from Plasmodium falciparum 3D7 strain," Biochem Biophys Res Commun., vol. 590, pp. 145-151, 2022.
[83] K. A. Moser, E. F. Drábek, A. Dwivedi, et al., "Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential," Genome Med., vol. 12, no. 1, p. 6, 2020.
[84] D. A. Van Schalkwyk, R. Burrow, G. Henriques, et al., "Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers," Malar J., vol. 12, no. 1, p. 320, 2013.